001046717 001__ 1046717
001046717 005__ 20251008122909.0
001046717 0247_ $$2doi$$a10.1093/noajnl/vdaf196
001046717 0247_ $$2datacite_doi$$a10.34734/FZJ-2025-03929
001046717 037__ $$aFZJ-2025-03929
001046717 082__ $$a610
001046717 1001_ $$00009-0007-1732-5759$$aStetter, Isabelle$$b0
001046717 245__ $$aPrediction of progression-free andoverall survival following temozolomide chemoradiation using FET PET-base,d parameter.s including radiomics in patients with glio blastorna
001046717 260__ $$aOxford$$bOxford University Press$$c2025
001046717 3367_ $$2DRIVER$$aarticle
001046717 3367_ $$2DataCite$$aOutput Types/Journal article
001046717 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759822350_28037
001046717 3367_ $$2BibTeX$$aARTICLE
001046717 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001046717 3367_ $$00$$2EndNote$$aJournal Article
001046717 500__ $$asupported by the Deutsche Forschungsgemeinschaft project number 428090865/SPP2177 (Norbert Galldiks, Philipp Lohmann, Keith George Ciantar)
001046717 520__ $$aBackground: Early after surgery and completion of first-line radiotherapy with concomitant temozolomide, the prediction of progression-free and overall survival (PFS, OS) is of considerable interest for managing patients with glioblastoma.Methods: Sixty-three newly diagnosed patients with glioblastoma (age range, 19-82 years) who received PET imaging using the radiolabeled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET) after surgery or biopsy and completion of radiotherapy with concomitant temozolomide were evaluated. Static FET PET parameters, that is, maximum and mean tumor-to-brain ratios (TBRmax, TBRmean), metabolic tumor volumes (MTV), and the dynamic FET PET parameters time-to-peak (TTP) and slope were obtained. Additionally, n = 1,303 FET PET radiomics features were extracted per patient, of which 15 robust features were selected for further evaluation based on test-retest analysis. The prognostic values of FET PET parameters and radiomics features were evaluated using receiver-operating-characteristic (ROC) analyses regarding a favorable PFS and OS. Subsequently, univariate and multivariate survival estimates were performed to assess the prognostic value of these parameters in predicting a significantly longer PFS and OS.Results: ROC analyses revealed that static parameters (ie, TBRmax, MTV) and one radiomics feature were the most powerful parameters to predict a significantly longer PFS (all P = .002) and OS (all P ≤ .02). In addition, the dynamic parameter TTP predicted a significantly longer OS (P ≤ .03) but not PFS (P > .05). TBRmax, MTV, and one radiomics feature remained significant in multivariate survival analysis (all P ≤ .03).Conclusion: Our results suggest that FET PET parameters, including radiomics, are highly prognostic in patients with glioblastoma at an early stage of first-line therapy.Keywords: artificial intelligence; glioma; prognosis.
001046717 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001046717 536__ $$0G:(GEPRIS)428090865$$aDFG project G:(GEPRIS)428090865 - Radiomics basierend auf MRT und Aminosäure PET in der Neuroonkologie (428090865)$$c428090865$$x1
001046717 588__ $$aDataset connected to DataCite
001046717 7001_ $$00000-0001-7147-4594$$aWerner, Jan-Michael$$b1
001046717 7001_ $$0P:(DE-Juel1)190394$$aWollring, Michael$$b2
001046717 7001_ $$0P:(DE-HGF)0$$aCeccon, Garry$$b3
001046717 7001_ $$0P:(DE-Juel1)203314$$aCiantar, Keith George$$b4$$ufzj
001046717 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b5
001046717 7001_ $$0P:(DE-Juel1)132318$$aMottaghy, Felix M$$b6$$ufzj
001046717 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R$$b7$$ufzj
001046717 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b8$$ufzj
001046717 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b9
001046717 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b10$$eCorresponding author$$ufzj
001046717 773__ $$0PERI:(DE-600)3009682-0$$a10.1093/noajnl/vdaf196$$gVol. 7, no. 1, p. vdaf196$$n1$$pvdaf196$$tNeuro-oncology advances$$v7$$x2632-2498$$y2025
001046717 8564_ $$uhttps://juser.fz-juelich.de/record/1046717/files/SOA25LT012481.pdf
001046717 8564_ $$uhttps://juser.fz-juelich.de/record/1046717/files/Invoice_SOA25LT012481.pdf$$yRestricted
001046717 8564_ $$uhttps://juser.fz-juelich.de/record/1046717/files/PDF.pdf$$yOpenAccess
001046717 8767_ $$8SOA25LT012481$$92025-09-29$$a1200217944$$d2025-10-08$$eAPC$$jZahlung erfolgt$$z2092 USD
001046717 909CO $$ooai:juser.fz-juelich.de:1046717$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
001046717 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)203314$$aForschungszentrum Jülich$$b4$$kFZJ
001046717 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b5$$kFZJ
001046717 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132318$$aForschungszentrum Jülich$$b6$$kFZJ
001046717 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
001046717 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
001046717 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b9$$kFZJ
001046717 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b10$$kFZJ
001046717 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001046717 9141_ $$y2025
001046717 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
001046717 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-18
001046717 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL ADV : 2022$$d2024-12-18
001046717 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
001046717 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-03T10:37:56Z
001046717 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-03T10:37:56Z
001046717 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
001046717 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
001046717 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
001046717 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001046717 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-03T10:37:56Z
001046717 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
001046717 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
001046717 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
001046717 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001046717 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
001046717 920__ $$lyes
001046717 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001046717 980__ $$ajournal
001046717 980__ $$aVDB
001046717 980__ $$aUNRESTRICTED
001046717 980__ $$aI:(DE-Juel1)INM-3-20090406
001046717 980__ $$aAPC
001046717 9801_ $$aAPC
001046717 9801_ $$aFullTexts